Educational content on VJDementia is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AAIC 2022 | Targeting neurotoxic proteins in neurodegenerative disease

Cheng Fang, PhD, Annovis Bio, Berwyn, PA, discusses the role of neurotoxic proteins in neurodegenerative disease and highlights clinical developments in targeting these proteins to preserve neuronal function. Overexpression of neurotoxic proteins results in a cascade that causes axonal transport deficits and impaired synaptic function in neurodegenerative disease. By preventing this, it is possible to protect axonal integrity and preserve synaptic function. A recent, double-blind, placebo-controlled Phase IIa study (NCT04524351) assessed the efficacy of buntanetap in lowering these neurotoxic protein levels in Alzheimer’s disease (AD). Results showed that buntanetap can lower neurotoxic proteins, improve axonal integrity and synaptic function, and lower inflammation in AD. This interview took place at the Alzheimer’s Association International Conference (AAIC) 2022 in San Diego, CA.


Cheng Fang is an employee of Annovis Bio.